Get the Stockscreener App
313.82
1.23%
3.81
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $313.82, with a volume of 1.30M.
It is up +1.23% in the last 24 hours and up +3.82% over the past month.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$310.01
Open:
$304.78
24h Volume:
1.30M
Relative Volume:
0.81
Market Cap:
$59.89B
Revenue:
$328.68B
Net Income/Loss:
$2.55B
P/E Ratio:
24.08
EPS:
13.0349
Net Cash Flow:
$1.56B
1W Performance:
-2.07%
1M Performance:
+3.82%
6M Performance:
-13.03%
1Y Performance:
+6.43%
1-Day Range:
$302.01
$314.31
1-Week Range:
$302.01
$333.95
52-Week Range:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
313.82 | 59.95B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
869.00 | 102.45B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
235.17 | 54.46B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
89.77 | 10.11B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.27 | 1.26B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-22-26 | Upgrade | Jefferies | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity - Yahoo Finance
Cencora (NYSE:COR) Releases FY 2026 Earnings Guidance - MarketBeat
5 Insightful Analyst Questions From Cencora’s Q2 Earnings Call - Yahoo Finance
If You Invested $1000 In Cencora Stock 10 Years Ago, You Would Have This Much Today - benzinga.com
Cencora (COR) Q2 2026 Earnings Call Transcript - fortune.com
Cencora, Inc. (COR) Stock Forecasts - Yahoo Finance
Cencora Inc (COR) Shares Fall 5.9% -- What GF Score of 77 Tells Investors - GuruFocus
Cencora: Walgreens Volume Disruption Raises New Concern, but We Make No Changes for Now - Morningstar
Cencora Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Cencora Inc Stock (COR) Closed Down by 5.92% on Aug 12: Key Drivers Unveiled - tradingkey.com
Cencora reaffirms $17.75-$17.95 FY26 EPS guidance amid Walgreens shift - scanx.trade
Cencora Says Certain Serviced Walgreens Volume Began Moving Outside Company; Reaffirms 2026 EPS Outlook - marketscreener.com
Cencora (COR) Reaffirms FY2026 Guidance as Walgreens Volume Tran - GuruFocus
Cencora maintains earnings guidance as some Walgreens volume moves away - Investing.com India
Cencora Reports Walgreens Volume Transition, Confirms FY2026 Adjusted EPS Forecast - Kalkine Media
Cencora dips on loss of some Walgreens business (COR:NYSE) - Seeking Alpha
Cencora says Walgreens volumes shift, reaffirms guidance, shares sink By Investing.com - Investing.com Canada
Form 8K Cencora Inc For: 12 August By Investing.com - Investing.com Canada
Cencora (NYSE:COR) Shares Gap DownWhat's Next? - MarketBeat
Is Wall Street Bullish or Bearish on Cencora Stock? - Yahoo Finance
Wedge Capital Management L L P NC Increases Position in Cencora, Inc. $COR - MarketBeat
Insight Wealth Strategies LLC Purchases 6,648 Shares of Cencora, Inc. $COR - MarketBeat
Cencora, Inc. (NYSE:COR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cencora, Inc. $COR Shares Sold by Handelsbanken Fonder AB - MarketBeat
Cencora Inc (COR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Cencora (COR) Posts Strong Q3 Earnings, Is The 9% Upside Enough? - simplywall.st
Cencora, Inc. (COR) Stock Analysis: Healthcare Distribution Giant with a 14.60% Upside Potential - DirectorsTalk Interviews
Cencora Inc (COR) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
The Bull Case For Cencora (COR) Could Change Following Raised EPS Outlook And Bigger Buybacks And Dividend - simplywall.st
Cencora Inc (COR) Stock News Today - TradingKey
Cencora Inc. stock underperforms Friday when compared to competitors - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Encourages Cencora, Inc. (COR) - The National Law Review
JPMorgan Adjusts Price Target on Cencora to $390 From $382 - Moomoo
Cencora, Inc. $COR Holdings Lifted by Assenagon Asset Management S.A. - MarketBeat
Corebridge Financial (COR) plans sale of 20,000 common shares under Rule 144 - Stock Titan
Leerink Partners Adjusts Price Target on Cencora to $380 From $368 - marketscreener.com
Evercore ISI Adjusts Price Target on Cencora to $350 From $330 - marketscreener.com
Citigroup Adjusts Price Target on Cencora to $370 From $355 - Yahoo Finance
Baird Adjusts Price Target on Cencora to $370 From $340 - Yahoo Finance
Cencora Expands Credit Facilities to Bolster Liquidity - The Globe and Mail
Cencora (COR) Stock Climbs As Margin Expansion Drives Profit Momentum - Sahm
Cencora, Inc. (COR) Stock forecasts - sg.finance.yahoo.com
Cencora, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Cencora, Inc. (NYSE:COR) Announces $0.60 Quarterly Dividend - MarketBeat
Cencora Inc (COR) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 73/100 - GuruFocus
Cencora Inc (COR) (Q3 2026) Earnings Call Highlights: Strong Double-Digit Growth and Raised Guidance - finance.yahoo.com
Cencora Inc (COR) (Q3 2026) Earnings Call Highlights: Strong Dou - GuruFocus
Strong Performance From Cencora's Specialty Assets Looks Durable and Offsets Industry Headwinds - Morningstar
Cencora Q3 fiscal 2026 slides show specialty strength, raised guidance - Investing.com
Cencora, Inc. 2026: Revenue $84.75B, EPS $3.94— 10-Q Summary - TradingView
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.70%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):